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In Brief
Benevento et al. reveal that the Kleefstrasyndrome-associated protein EHMT1 regulates synaptic scaling through histone methylation. EHMT1 contributes to control an epigenetic repressive genetic program required to scale up synapses in response to chronic network activity deprivation.
INTRODUCTION
Experience-dependent neuronal activity is crucial for promoting long-lasting modifications at functional synapses during development and in adulthood. To preserve neural network stability, a mechanism exists that maintains firing rates within a physiological range of activity. Neurons can continuously adapt their firing rates through synaptic and intrinsic cellular mechanisms, a process generally referred to as homeostatic plasticity (Turrigiano and Nelson, 2004; Turrigiano, 2012) . Disrupted homeostatic plasticity appears in several neurodevelopmental disorders, including fragile X syndrome, Rett syndrome, and tuberous sclerosis, suggesting that improper circuit refinement during development contributes to cognitive impairment (Corté s-Mendoza et al., 2013; Soden and Chen, 2010; Zhong et al., 2012) .
Synaptic scaling, a well-characterized form of homeostatic plasticity, stabilizes neuronal network activity by balancing excitation and inhibition. This occurs through bidirectional modulation of cell-wide synaptic strength, where prolonged unidirectional neuronal activity receives negative feedback (Turrigiano, 2012 ). An important mechanism underlying synaptic scaling at glutamatergic synapses involves regulated trafficking of AMPA receptors into and out of the post-synaptic membrane (Diering et al., 2014; Pozo and Goda, 2010; Turrigiano, 2012) . Chronic network activity elicits AMPA receptor removal, whereas chronic suppression increases synaptic AMPA receptor abundance (Goold and Nicoll, 2010) . Mounting evidence indicates that the intricate regulation of AMPA receptor trafficking during synaptic scaling requires de novo gene transcription and depends on intracellular Ca 2+ -signaling (Ibata et al., 2008; Thiagarajan et al., 2005) . Experiments have indeed shown that bidirectional scaling is prevented by the transcription inhibitor actinomycin D (Goold and Nicoll, 2010; Han and Stevens, 2009; Ibata et al., 2008) . Also, chronic neuronal activity or suppression respectively activates or inactivates calcium/calmodulin-dependent protein kinase type IV (CaMKIV) (Goold and Nicoll, 2010; Ibata et al., 2008) . This indicates that gene transcription through CaMKIV signaling plays a pivotal role in bidirectional scaling. Specifically, transcriptional repression of Arc and Bdnf is required for synaptic scaling up during chronic network suppression (Bé ïque et al., 2011; Gao et al., 2010; Rutherford et al., 1998; Shepherd et al., 2006) . Since synaptic scaling requires gene transcription, a picture is emerging that implicates epigenetic regulation in homeostatic plasticity. Several studies have shown that DNA-methylation at the Bdnf promoter is dynamically regulated in an activity-dependent manner (Chang et al., 2010; Levenson et al., 2006; Lubin et al., 2008; Martinowich et al., 2003) . Also methyl-CpG binding protein 2 (MeCP2) and Tet3 are required for synaptic scaling (Blackman et al., 2012; Qiu et al., 2012; Zhang et al., 2014; Zhong et al., 2012; Yu et al., 2015) and the RE1-silencing transcription factor (REST)/neuron-restrictive silencer factor (NRSF) complex is required for intrinsic homeostatic plasticity induced by sustained electrical activity in hippocampal neurons (Pozzi et (B) Quantitative analysis of H3K9me2 levels in neurons (MAP2 positive) and glial (MAP2-negative) cells treated with PTX or TTX for 48 hr and untreated (NT). Data are presented as mean ± SEM. ***p < 0.001; n = 34-41; n.s., non-significant; glia p > 0.05; one-way ANOVA.
(C) Quantitative analysis of time course of H3K9me2 levels in TTX-treated neurons. Data are presented as mean ± SEM. *p < 0.05; ***p < 0.001; n.s., nonsignificant; n = 20-25; one-way ANOVA.
(D) Analysis of reversibility of TTX-induced H3K9me2 changes. H3K9me2 intensity expressed as mean ± SEM fold change from NT cultures. ***p < 0.001; n = 23-27; one-way ANOVA.
(E) Quantitative analysis of H3K9me2 levels in conditions as indicated. Data are presented as mean ± SEM fold change from NT cultures. ***p < 0.001; n = 28-50; n.s., non-significant; two-way ANOVA.
(F) Representative images of H3K9me2 immunofluorescence levels in neurons transfected with control vector, Ehmt1#1, Ehmt1#2, or Ehmt1#1 + Ehmt1-OE in untreated (NT) neurons and neurons treated with TTX for 48 hr. Scale bar, 5 mm.
(G) Representative images of H3K9me2 immunofluorescence levels of untreated or TTX-treated neurons (48 hr) with UNC0638 (48 hr). Scale bar, 5 mm.
(legend continued on next page) 2013). While evidence that epigenetic mechanisms are critical for synaptic scaling is mounting, it is currently unknown which chromatin modifications are involved and how they are regulated. Disrupted epigenetic regulation is commonly found in neurological disorders such as intellectual disability (ID) (Kleefstra et al., 2014) , autism spectrum disorder (ASD) (De Rubeis et al., 2014) , and schizophrenia (McCarthy et al., 2014) . Haploinsufficiency of the euchromatic histone-lysine N-methyltransferase 1 (EHMT1) gene casues Kleefstra syndrome (Kleefstra et al., 2006 (Kleefstra et al., , 2009 (Kleefstra et al., , 2012 and is associated with some cases of ASD (Talkowski et al., 2012) and schizophrenia (Kirov et al., 2012) . EHMT1 (GLP), together with its paralog, EHMT2 (G9a), forms a chromatin remodeling complex that catalyzes the dimethylation of histone H3 at lysine 9 (H3K9me2), a post-translational modification associated with transcriptional repression (Tachibana et al., 2005) . Interestingly, H3K9me2 is an epigenetic mark that is dynamically regulated in the hippocampus and nucleus accumbens during contextual fear memory formation, addiction, and stress (Boulle et al., 2014; Chase and Sharma, 2013; Covington et al., 2011; Gupta et al., 2010; Gupta-Agarwal et al., 2012 Heller et al., 2014; Maze et al., 2010) . Genetic and pharmacological manipulations of EHMT1/2 in vivo have also shown that EHMT signaling is important for long-term memory formation both in mouse and Drosophila (Balemans et al., 2013; Gupta-Agarwal et al., 2012; Kramer et al., 2011; Schaefer et al., 2009) .
Here, we report that H3K9me2 is bidirectionally regulated by chronic changes in neuronal activity. We show that EHMT1 and EHMT2 are part of a complex that regulates a transcriptional program essential for synaptic scaling. Specifically, EHMT1 and EHMT2 are required for the increase in H3K9me2 when network activity is chronically inhibited and for synaptic scaling up in vitro and in vivo. Moreover, we found that EHMT1 and EHMT2 repressed Bdnf expression during synaptic scaling up by increasing H3K9me2 at Bdnf promoter IV. We posit that EHMT1 and EHMT2 act as cell-autonomous epigenetic regulators that govern a repressive program required for synaptic scaling up.
RESULTS

Neuronal Activity Elicits Dynamic Effects on Synaptic Scaling via H3K9me2
We first investigated whether chronic neuronal network manipulation alters the methylation levels of H3K4 (H3K4me1, H3K4me3), H3K9 (H3K9me2), or H3K27 (H3K27me3). We treated cultures of rat primary cortical neurons for 48 hr beginning at 11 days in vitro (DIV) with either 1 mM tetrodotoxin (TTX) or 10 mM picrotoxin (PTX) to induce homeostatic scaling up or scaling down, respectively . The fluorescence intensity of immunolabeled H3K9me2 (Vedadi et al., 2011) revealed that nuclear H3K9me2 increased significantly in TTX-treated compared to untreated neurons, whereas H3K9me2 decreased significantly in neurons treated with PTX ( Figures 1A and 1B) . In a mixed primary culture, H3K9me2 was most prominently detected in MAP2-positive neurons ( Figure 1A ). Accordingly, we did not observe any network activity-dependent changes in H3K9me2 within MAP2-negative glial cells ( Figure 1B) , suggesting that changes in H3K9me2 were restricted to neurons. Although we did observe less pronounced changes in H3K4me3 and H3K27me3, they were not bidirectionally correlated with synaptic scaling up or down ( Figure S1A ).
Synaptic scaling is a progressive process that develops gradually over a period of 48 hr (Ibata et al., 2008; Sutton et al., 2006) . To evaluate the temporal dynamics of H3K9 dimethylation induced by TTX, we measured H3K9me2 fluorescence at sequential time points after adding TTX. H3K9me2 fluorescence was significantly elevated by 12 hr, further enhanced at 24 hr, and plateaued from 36 to 48 hr after TTX treatment ( Figure 1C ). Synaptic scaling is also a reversible process (Goel and Lee, 2007; Goel et al., 2011) ; therefore, we investigated the effect of removing TTX on H3K9me2 in our neuronal cultures. Cultures were first treated with TTX for 48 hr. The medium was then refreshed with pre-conditioned untreated culture medium, and H3K9me2 fluorescence intensity was measured 48 hr later. Interestingly, after TTX was withdrawn, we found that H3K9me2 fluorescence in treated neurons returned to an intensity equal with untreated neurons ( Figure 1D ).
Various protocols that reduce Ca 2+ influx are used to induce synaptic scaling in cultured neurons. These include blocking L-type calcium channels or AMPA receptor function, respectively, with nimodipine or CNQX for 48 hr (Lee et al., 2013; Wierenga et al., 2005; Thiagarajan et al., 2005 , Ibata et al., 2008 . Either nimodipine or CNQX alone increased H3K9me2 fluorescence, but they occluded the TTX-induced increase in H3K9me2 ( Figures 1E and S1B ). In contrast, blocking NMDAdependent calcium influx with APV for 48 hr did not increase H3K9me2 nor was there a cumulative effect when combined with TTX (Figures 1E and S1B) . Furthermore, the TTX-induced increase in H3K9me2 was prevented (Figures 1E and S1B) when endoplasmic reticulum calcium reuptake was blocked by thapsigargin (Lee et al., 2013) . To identify Ca
2+
-dependent signaling pathways upstream of H3K9me2, we pharmacologically blocked CaMK signaling. Previous studies showed that chronic network suppression reduced CaMKIV-and CaMKK-mediated phosphorylation due to decreased intracellular calcium (Thiagarajan et al., 2005; Ibata et al., 2008) . We used STO-609 to block CaMKK, which in turn inhibits CaMKIV (Ibata et al., 2008) . STO-609 treatment increased H3K9me2, comparable to TTX treatment (Figures 1E and S1B) , suggesting that TTX reduces CaMKK/CaMKIV signaling and this pathway directly contributes to increased H3K9me2 during synaptic scaling up. Collectively, these experiments indicate that chronically increased or decreased neuronal activity bidirectionally alters H3K9me2 levels in cortical neurons.
(H) Quantitative analysis of H3K9me2 levels in neurons transfected with control vector, Ehmt1#1, Ehmt1#2, Ehmt1#1 + Ehmt1-OE, or UNC0638 in untreated (NT) neurons and neurons treated with TTX for 48 hr. Data are presented as mean ± SEM fold change from NT. *p < 0.05; ***p < 0.001; n = 21-41; n.s., non-significant; two-way ANOVA. See also Figure S1 . (legend on next page)
EHMT1 Is Required for the TTX-Dependent Increase in Neuronal H3K9me2
Since EHMT1 catalyzes H3K9 dimethylation, we focused on the role of EHMT1 in synaptic scaling up. We first evaluated whether EHMT1 is required for the TTX-dependent increase in H3K9me2 by designing GFP-expressing constructs to encode small hairpin RNA (shRNA) sequences (Ehmt1#1-4) that specifically knock down EHMT1 in neurons ( Figure S1C ). We sparsely transfected cortical cultures with either control vector or shRNA-expressing vectors (Ehmt1#1 or Ehmt1#2) at DIV 0. Cultures were then treated at DIV 11 with TTX for 48 hr. H3K9me2 fluorescence was measured in transfected (GFP+) and untransfected (GFPÀ) neurons and compared to untreated neurons. As expected, we found that TTX increased H3K9me2 in GFPÀ and GFP+ neurons treated with the control vector. Conversely, TTX did not increase H3K9me2 in neurons transfected with either of the Ehmt1 hairpins ( Figures 1F and 1H ). Moreover, we observed that basal H3K9me2 fluorescence, before adding TTX, was significantly lower in neurons transfected with the Ehmt1 hairpins ( Figures 1F and 1H ). Importantly, co-transfection of Ehmt1#1, which targets the 3 0 UTR of the endogenous Ehmt1 mRNA, together with a construct that overexpresses mouse Ehmt1 cDNA (Ehmt1-OE), restored both basal H3K9me2 levels and the TTX-induced increase (Figures 1F and 1H) .
Next, we pharmacologically blocked the methyltransferase activity of EHMT1 and EHMT2 with UNC0638 (Vedadi et al., 2011) . We treated neurons with UNC0638 in the presence or absence of TTX and measured the immunofluorescence intensity of H3K9me2. UNC0638 blocked the increase in H3K9me2 by TTX ( Figures 1G and 1H ). We also found that UNC0638 alone reduced the basal H3K9me2 levels, similar to Ehmt1#1 and Ehmt1#2 ( Figures 1F-1H ). These results suggest that EHMT1, through activity-dependent dimethylation of H3K9, functions as an epigenetic regulator of homeostatic synaptic scaling up.
EHMT1 Is Required for the TTX-Dependent Increase in mEPSC Amplitude
To determine if EHMT1 is required for homeostatic synaptic scaling up, we recorded miniature excitatory postsynaptic currents (mEPSCs) from untreated and TTX-treated neurons that were transfected with Ehmt1#1, Ehmt1#2, or control vector. Consistent with previous observations, TTX significantly increased mEPSC amplitudes recorded from untransfected and control neurons (Figures 2A and 2B ), but not mEPSC frequency ( Figure S2A ) (Hou et al., 2008; Kim and Ziff, 2014; Wierenga et al., 2006) . However, when EHMT1 was knocked down, mEPSC amplitudes did not increase in response to chronic TTX treatment (Figures 2C and 2D) . We also found that neurons co-transfected with Ehmt1#1 and Ehmt1-OE had increased mEPSC amplitudes after TTX treatment, similar to control neurons ( Figure 2E ). Therefore, specific knockdown of EHMT1 appears to prevent synaptic scaling up. We then recorded mEPSCs from neurons treated with either UNC0638 alone or in combination with TTX. Inhibiting EHMT1/2 with UNC0638 alone for 48 hr had no effect on either mEPSC amplitude or frequency compared to untreated neurons, whereas synaptic scaling up was impeded in neurons co-treated with UNC0638 and TTX ( Figure 2F ). Collectively, these findings provide further evidence that EHMT1 is required for homeostatic scaling up.
Interestingly, we found that pharmacological inhibition or genetic knockdown of Ehmt1, despite reducing basal H3K9me2 fluorescence ( Figures 1F-1H ), did not affect basal mEPSC amplitude or frequency ( Figure S2A ). To investigate whether increasing H3K9me2 levels was sufficient to scale up synapses, we used the class-1 HDAC inhibitor MS-275. When used in combination with cocaine, MS-275 was shown to enhance Ehmt1/2 expression and subsequently raise H3K9me2 levels in the nucleus accumbens (Kennedy et al., 2013) . Treating neurons with MS-275 alone for 48 hr significantly increased H3K9me2 fluorescence ( Figure S2B ); however, it did not increase mEPSC amplitude ( Figure S2C ). We therefore propose that EHMT1 acts as an epigenetic regulator that represses a genetic program required, but not sufficient, for homeostatic synaptic scaling up.
EHMT1 Is Required for Surface AMPA Receptor Expression upon TTX Induction
Previous studies have shown that neurons increase their mEPSC amplitudes by increasing the surface expression of AMPA receptors GluA1 and GluA2 (Diering et al., 2014; Gainey et al., 2009 ). We performed live-cell fluorescent labeling of surface GluA1 and GluA2 and compared the signal between control and TTX-treated neurons (Wierenga et al., 2005) . TTX caused a significant increase in fluorescent puncta in control neurons (Figure 2G) , but not in Ehmt1#2-transfected neurons ( Figure 2G ). We conclude that Ehmt1 knockdown prevents increased surface expression of AMPA receptors during synaptic scaling up, which supports our notion that EHMT1 protein is required for this process.
EHMT1/EHMT2 Complex Is Required for Synaptic
Scaling Up EHMT1 interacts with EHMT2 to form a functional complex that catalyzes H3K9 dimethylation (Tachibana et al., 2008; . Thus, the TTX-mediated increase in H3K9me2 may be caused by the modulation of gene or protein expression levels of Untransfected neurons (NT, TTX, n = 9-11), (B) neurons transfected with a control vector (NT, TTX, n = 10-11), (C) neurons transfected with shRNA Ehmt1#1 (NT, TTX, n = 10-11), (D) neurons transfected with hairpin Ehmt1#2 (NT, TTX, n = 8-8), (E) neurons co-transfected with Ehmt1#1+Ehmt1-OE (NT, TTX, n = 11-14), and (F) UNC0638-treated neurons (NT, TTX, n = 10-10) are shown. ***p < 0.001; n.s., non-significant; two-way ANOVA. Vertical scale, 25 pA; horizontal scale, 50 ms. (G) Representative images of GluA1 and GluA2 surface immunoreactivity in control vector and Ehmt1#2 transfected neurons, untreated (NT) or TTX treated (TTX) (48 hr). Scale bar, 5 mm. Immunoreactivity intensity quantification analysis expressed as fold change from NT. *p < 0.05; ***p < 0.001; n.s., non-significant. GluA1: control vector NT, TTX n = 8-10; Ehmt1#2 NT, TTX, n = 8-8. GluA2: control vector NT, TTX n = 8-8; Ehmt1#2 NT, TTX, n = 8-8; two-way ANOVA. See also Figure S2 . EHMT1, EHMT2, or both. Alternatively, neuronal activity could change the subcellular distribution of EHMT1/2, similar to histone deacetylases such as HDAC4 (Sando et al., 2012) . To assess these possibilities, we analyzed the distribution of EHMT1 and EHMT2 after TTX treatment. EHMT1 and EHMT2 were primarily expressed in the nucleus under normal conditions, and TTX treatment did not change their subcellular localization ( Figures S3A and S3B) . Next, we examined EHMT1 and EHMT2 protein and mRNA levels before and after TTX treatment. TTX caused a significant increase in both the short and long isoforms and total EHMT2 protein levels, but EHMT1 protein levels Figure 2B ); Ehmt2#1 NT, TTX, n = 10-10; Ehmt2#3 NT, TTX. n.s., non-significant; n = 9-8; two-way ANOVA. See also Figure S3 .
were unaffected (Figures 3A and 3B) . Consistent with previous studies (Bateup et al., 2013a; Shepherd et al., 2006) , we found that ARC protein levels were significantly reduced after TTX treatment (Figures 3A and 3B) . Transcriptional regulation has been shown to occur as early as 4 hr after TTX treatment (Ibata et al., 2008) . To determine when changes in EHMT1/2 occur, we profiled Ehmt1 and Ehmt2 mRNA expression at two time points after TTX treatment (4 and 48 hr). Ehmt2 mRNA levels were significantly increased after 48 hr, but not after 4 hr ( Figure S3C ). Ehmt1 expression, however, did not change and was comparable to untreated neurons at both time points ( Figure S3C ).
Since EHMT1 dimerizes with EHMT2 to form a functional complex (Tachibana et al., 2005 (Tachibana et al., , 2008 , we hypothesized that the TTX-dependent increase in H3K9me2 levels may result from an enhanced interaction leading to higher enzymatic activity. First, we measured enzymatic activity using an ELISA-based assay for histone methyltransferase (HMT) and found increased HMT activity in nuclear extracts from TTX-treated neurons ( Figure 3C ). Next, using nuclear protein lysates, we co-immunoprecipitated EHMT2 with an EHMT1 antibody. Similar to previous findings (Tachibana et al., 2005) , EHMT2 co-immunoprecipitated with EHMT1 ( Figure 3D ). Interestingly, western blot analysis showed that TTX treatment significantly increased the interaction between EHMT1 and EHMT2 ( Figure 3D ).
Based on these results, we hypothesized that EHMT2 is also required for the functional expression of homeostatic scaling up. We designed and validated two independent shRNAs (Ehmt2#1 and Ehmt2#3) to downregulate endogenous EHMT2 ( Figure S3E ). Chronic TTX treatment failed to increase H3K9me2 levels and scale up in neurons transfected with either Ehmt2#1 or Ehmt2#3 (Figures 3E-3H) . Interestingly, we found that knocking down Ehmt2 specifically reduced mEPSC frequency but did not affect amplitude in basal conditions (Figure S3F) , suggesting a specific function for EHMT2 in early synapse formation. Indeed, EHMT2-deficient, but not EHMT1-deficient, cortical neurons showed fewer juxtaposing PSD-95/ VGLUT puncta and hence fewer synapses ( Figure S3F ). However, neither Ehmt1 knockdown nor Ehmt2 knockdown affected neurite outgrowth ( Figure S3G ). Collectively, our data suggest that chronic network deprivation activates a repressive program whereby upregulated EHMT1-EHMT2 complex increases H3K9me2 and scales up synapses.
EHMT1 Is Required for TTX-Induced Gene Repression
Next, we sought to decipher the genetic program that is associated with synaptic scaling up. We generated strand-specific RNA sequencing (RNA-seq) libraries from wild-type (WT) and Ehmt1#2 transduced neuronal cultures, with and without TTX treatment. In Ehmt1#2 neurons, Ehmt1 transcript was significantly downregulated (DEseq2, p < 0.026, log 2 (fc) = À0.61), whereas Ehmt2 transcript remained unaffected (DEseq2, p < 0.43, log 2 (fc) = À0.21). In the absence of TTX treatment, Ehmt1#2 exhibited differential expression of a relative small number of genes, with an equal amount of down and upregulated genes (89 upregulated genes, and 88 downregulated genes, DEseq2 p < 0.01; Figure 4A ). TTX-treatment of WT neurons induced a larger change in the number of genes, and Spearman correlations sharply segregated the untreated and TTX-treated conditions (301 genes; Figure 4B ). TTX treatment of WT neurons mostly triggered gene repression, since the number of downregulated genes was $7-fold higher than upregulated ones (263 against 38; Figure 4C ). Also TTX treatment of Ehmt1#2 neurons led to a significant downregulation, but only a partial overlap was found with the genes downregulated in WT neurons ( Figures  4C, left, S4A , and S4B). Upregulated genes were few in both conditions, and the overlap was low ( Figure 4C, right) . Interestingly, we found a significant reduction in the global TTX-induced repression of Ehmt1#2 neurons as compared to control neurons (p < 5.8e-13; Figure 4D ). Moreover, in Ehmt1#2 neurons, the TTX responsive genes showed significantly higher basal expression level ( Figure 4E ), suggesting that these genes are directly or indirectly controlled by EHMT1. Overall, these data indicate that in Ehmt1#2 neurons the TTX-induced repression is impaired and suggest that a subset of TTX-responsive genes is EHMT1 dependent. When looking in greater detail at individual genes, we found that $30% of the genes normally repressed in WT neurons by TTX were not repressed in EHMT1-deficient neurons ( Figures 4F and  S4C ). This subset of genes can therefore be categorized as EHMT1 dependent. We performed Gene Ontology (GO) enrichment analysis to gain insights into the functional properties of TTX-responsive genes ( Figure 4G) . Genes downregulated by TTX treatment are implicated in a number of processes, including cholesterol biosynthesis (p < 2e-6), potassium ion channels (p < 6e-7), calcium signaling (p < 4e-6), and synaptic transmission (p < 4e-7). Interestingly, EHMT1-dependent and EHMT1-independent genes segregated in different functional groups. More precisely, Ehmt1#2 neurons were unable to properly repress genes linked to ion channels (p < 1.5e-5), synaptic vesicle (p < 1.4e-4), and calcium signaling (p < 1.4e-5). On the other end, the modulation of the cholesterol biosynthesis was normal in Ehmt1#2 neurons (p < 5.7e-11), suggesting that this specific pathway does not seem to be dependent on EHMT1.
Chronic Neuronal Deprivation Induces EHMT1/2-Mediated Repression of BDNF Our RNA-seq analysis revealed that Bdnf is misregulated in Ehmt1#2 transduced neurons. BDNF is a growth factor secreted from excitatory neurons that bidirectionally modulates homeostatic synaptic scaling, and Bdnf (exon IX) repression is known to be required for synaptic scaling up Desai et al., 1999; Lindskog et al., 2010) . We therefore validated Bdnf IX mRNA expression, which is the most common Bdnf splicing variant (Aid et al., 2007) (Figure 5A ). Together with Bdnf IX, we analyzed a set of EHMT1-dependent and EHMT1-independent TTX-responsive genes, including Arc, Rab3b, and Prnp, by performing real-time qPCR ( Figure S4D ). We were intrigued to find that in Ehmt1#2 transduced neurons, basal Bdnf IX mRNA was high, and it was not repressed by TTX (Figure 5A ), indicating that EHMT1 is required for TTX-mediated repression of BDNF. Furthermore, UNC0638 also prevented Bdnf mRNA repression in neurons that were co-treated with TTX ( Figure S5A) .
Previous studies have shown that BDNF decreases in response to chronic network deprivation (Castré n et al., 1992; Karpova et al., 2010) , and exogenous BDNF can block synaptic scaling up in pyramidal neurons (Desai et al., 1999; Rutherford et al., 1998) . In addition, scavenging BDNF with tyrosine receptor kinase B immunoglobulin g (TrkB-Ig) was sufficient to induce synaptic scaling up in neuronal cultures. We therefore hypothesized that scavenging excess BDNF from Ehmt1#2 transduced neurons with a soluble form of TrkB receptor (TrkB fragment crystallizable [TrkB-FC]) could restore plasticity. First, we confirmed that BDNF blocked synaptic scaling up when neurons were co-treated with TTX, whereas BDNF alone did not have any effect on mEPSC amplitudes (Figure 5B ). Applying TrkB-FC alone to the neuronal cultures was sufficient to augment mEPSC amplitudes ( Figure 5B ). Synaptic scaling up was restored in Ehmt1 shRNA#2 transduced neurons when cotreated with TTX and TrkB-FC ( Figure 5C ). These results strongly suggested that synaptic scaling up is achieved at least in part through H3K9me2-mediated repression of BDNF.
Previous studies have shown that BDNF expression is regulated by H3K9me2 occupancy at Bdnf promoter IV in the nucleus (legend continued on next page) accumbens when stimulated by cocaine (Maze et al., 2010) and at Bdnf promoters I, IV, and IXa in primary rat cortical neurons when stimulated by nicotine (Chase and Sharma, 2013) . We immunoprecipitated chromatin (ChIP) with EHMT1 and EHMT2 antibodies, separately, and analyzed their enrichment at four Bdnf promoter regions. EHMT1 and EHMT2 occupancy was specifically enriched at Bdnf promoter IV after TTX treatment ( Figure 5D ). Next, we performed H3K9me2 ChIP-qPCR and confirmed that in TTX-treated WT neurons H3K9me2 occupancy was also increased at BDNF promoter IV, with no significant changes in other Bdnf promoter regions ( Figure 5E ). In contrast, H3K9me2 enrichment at the Bdnf promoter regions in Ehmt1#2 transduced neurons was significantly lower compared to untreated WT neurons and lacked any kind of regulation after TTX treatment ( Figure 5E ). Accordingly, TTX did not alter H3K9me2 enrichment in either EHMT2-deficient or UNC0638-treated neurons ( Figure S5D ). Together, these results suggest that the EHMT1/2 complex modifies chromatin specifically at Bdnf promoter IV by increasing H3K9me2 during synaptic scaling up.
EHMT1 Is Required for Homeostatic Synaptic Scaling
In Vivo Synaptic scaling can be induced in mice by R2 days of light deprivation (Desai et al., 2002; Goel et al., 2011; Maffei and Turrigiano, 2008) . Light deprivation paradigms cause scaling up at glutamatergic synapses of layer II/III pyramidal neurons in the primary visual cortex (V1) of p21 and adult mice (Goel and Lee, 2007) . This suggests that synaptic scaling plays a critical role in experience-dependent development. We evaluated H3K9me2 fluorescence and mEPSCs in V1 after 3 days of light deprivation (dark-reared [DR]), comparing WT to Ehmt1 +/À mice, since the Ehmt1 +/À mouse recapitulates core features of Kleefstra syndrome (Balemans et al., 2010 (Balemans et al., , 2013 (Balemans et al., , 2014 . H3K9me2 fluorescence was significantly higher in NeuN-positive V1 layer II/III cells of WT DR mice ( Figures 6A and 6B ). In contrast, H3K9me2 was not significantly different between normal-reared (NR) and DR Ehmt1 +/À mice ( Figures 6A and 6B ). In addition, basal H3K9me2 levels were significantly lower in Ehmt1 +/À mice, compared to WT. These data support our observations in primary cortical neurons, where chronic activity deprivation induces an EHMT1-dependent increase in neuronal H3K9me2.
To evaluate the effect of light deprivation on synaptic strength, we recorded mEPSCs in layer II/III pyramidal neurons from acute slices of V1. As previously shown (Desai et al., 2002; Goel et al., 2011; Maffei and Turrigiano, 2008) , mEPSC amplitudes increased significantly in WT DR mice ( Figures 6C and 6D) . However, DR Ehmt1 +/À mice did not show an increase in mEPSC amplitudes compared to NR Ehmt1 +/À mice ( Figures 6C and   6D ). The basal amplitude of the mEPSCs was not different between the genotypes, nor did we find any differences in the frequency of mEPSCs between the genotypes or between the treatments ( Figure S6A ). We showed in vitro that EHMT1 is required for synaptic scaling up and increases H3K9me2 at Bdnf promoter IV ( Figures 5A, 5D , and 5E). We next tested whether this was also the case in vivo. To this end, we measured mRNA expression (qPCR) and H3K9me2 enrichment (ChIP-qPCR) in V1 from NR or DR WT and Ehmt1 +/À mice ( Figures 6E and 6F ). Dark rearing did not affect Ehmt1 mRNA expression in WT mice, which was significantly lower in the Ehmt1 +/À mice ( Figure 6E ). Instead, Ehmt2 mRNA expression increased significantly in DR WT mice (Figure 6E) . Importantly, we found that dark rearing downregulated Bdnf mRNA expression in WT mice, confirming previous observations (Karpova et al., 2010) . Bdnf mRNA downregulation was also associated with an increase in H3K9me2 at Bdnf promoter IV ( Figure 6F ). In contrast, DR Ehmt1 +/À mice were unable to repress Bdnf expression ( Figure 6E ) and did not show an increase in H3K9me2 at Bdnf promoters I, IV, and VI ( Figures 6F  and S6C ). In accordance with our in vitro data ( Figure S4D ), Rab3b and Arc mRNA were significantly downregulated in DR WT mice, but not in DR Ehmt1 +/À mice ( Figure S6B ). In contrast,
Prnp expression was significantly downregulated irrespective of the genotype, indicating that Prnp regulation is independent of EHMT1 activity ( Figure S6B ). Similar to Bdnf, we found that Rab3b mis-repression in Ehmt1 +/À mice correlated with insufficient H3K9me2 enrichment at the Rab3b promoter ( Figure S6C ), suggesting that Rab3b expression depends on H3K9me2. This was not the case for Arc ( Figure S6C ). Finally, we did not find any significant changes in H3K9me2 levels at the Actin promoter, confirming the specificity of our results ( Figure S6C ).
These results provide evidence that EHMT1 is required for homeostatic scaling up after sensory deprivation in vivo and suggest that the increase in mEPSC amplitudes parallels the rise in H3K9me2 levels, which represses Bdnf expression.
DISCUSSION
Role of EHMT1 and EHMT2 in Homeostatic Plasticity
In this study, we provide several lines of evidence for the requirement of EHMT1 and EHMT2 for synaptic scaling up. First, sustained chronic deprivation or activation in primary cortical neurons increased or decreased H3K9me2 levels, respectively. Similarly, chronic visual deprivation resulted in increased H3K9me2 levels in layer II/III of the mouse visual cortex. Second, the changes in H3K9me2 were pivotal for the functional expression of synaptic scaling since genetic or pharmacological (F) Behavior of TTX-repressed genes (WT neurons) in Ehmt1#2 neurons. The pie chart represents all the genes (263, p < 0.01) that are downregulated by TTX in WT neurons and divided in groups according to their downregulation in Ehmt1#2 neurons (based on their p value). Dark gray group encompasses those genes that in Ehmt1#2 neurons are downregulated by TTX with the same strength as in WT neurons (p < 0.01). Bright gray area features genes that are downregulated in Ehmt1#2, but with milder strength (p < 0.05). Light blue delimits an intermediate area with uncertain behavior. Dark blue area isolates those genes that in Ehmt1#2 neurons are not downregulated after TTX treatment. (G) EHMT1-dependent and independent functional pathways related to homeostatic plasticity. The radar plot shows GO enrichment main terms and scores (Benjamini-adjusted p values, represented in Z score scale) for the 263 genes downregulated by TTX. Groups are divided as in (F). Outer rings correspond to higher enrichment. Threshold for p < 0.01 is indicated by the red circle. See also Figure S4 . 
Figure 5. EHMT1 and EHMT2 Repress BDNF Expression to Scale Up Synapses
(A) qPCR analysis of Bdnf exon IX mRNA levels in control vectors and Ehmt1#2 transduced neurons treated with TTX (48 hr) or untreated. Data are presented as mean ± SEM. ***p < 0.001; n.s., non-significant; n = 6; two-way ANOVA.
(B) Cumulative plots and mEPSC amplitude bar graphs of control neurons in conditions as indicated: untreated (NT), TTX, BDNF (25 ng/ml), BDNF + TTX or TrkB-FC (500 ng/ml). All drugs were added for 48 hr. Data are presented as mean ± SEM. ***p < 0.001; n.s., non-significant; n = 10; one-way ANOVA.
(C) Cumulative plots and mEPSC amplitude bar graphs of Ehmt1#2 transduced neurons, in conditions as indicated: untreated (NT), TTX or TrkB-FC (500 ng/ml) (48 hr). Data are presented as mean ± SEM. ***p < 0.001; n.s., non-significant; n = 10; two-way ANOVA. D) Chromatin immunoprecipitation with EHMT1 and EHMT2 antibody and qPCR analysis of the specified Bdnf promoter I, IV, VI, exon IX, and Actin promoter from WT neurons treated with TTX (48 hr) or untreated, expressed as EHMT1 or EHMT2% input recovery. Data are presented mean as mean ± SEM, n = 4-4 ; *p < 0.05; ***p < 0.001; n.s., non-significant; t test. Above the bar graphs, Bdnf gene structure is depicted. Each blue box represents an exon, while the red boxes indicate the promoter sequences analyzed and their position within the rat Bdnf gene.
(E) Chromatin immunoprecipitation with H3K9me2 and qPCR analysis of the specified Bdnf promoter I, IV, VI, exon IX, and Actin promoter from WT and transduced with Ehmt1#2 neuronal cultures, untreated (NT) or TTX treated (48 hr), expressed as H3K9me2% input recovery. Data are presented as mean ± SEM, n = 8-8; *p < 0.05; ***p < 0.001; n.s., non-significant; two-way ANOVA. Above the bar graphs, Bdnf gene structure is depicted. Each blue box represents an exon, while the red boxes indicate the promoter sequences analyzed and their position within the rat Bdnf gene. See also Figure S5 .
blockade of EHMT1/2 in vitro prevented the increases in H3K9me2, mEPSC amplitudes, and synaptic expression of AMPA receptors. Furthermore, visual deprivation did not cause synaptic scaling up in Ehmt1 +/À mice. Third, EHMT1 and EHMT2 occupancy and H3K9me2 deposition were increased at the Bdnf promoter IV after chronic activity suppression. Consequently, loss of EHMT1 or EHMT2 prevented Bdnf repression during synaptic scaling up. Together, our data indicate that EHMT1 and EHMT2 comprise a repressive epigenetic complex that is engaged during synaptic scaling up. Specifically, we found that chronic activity suppression upregulated EHMT2 protein levels, leading to more EHMT1/2 complex. Previous studies showed that H3K9me2 is catalyzed by the EHMT1-EHMT2 heteromer and is enriched at the promoters of silenced genes (Tachibana et al., 2002) . A direct correlation between EHMT1/2 expression, H3K9me2, and gene repression was shown in studies where chronic cocaine abuse decreased EHMT1 and EHMT2 levels in the nucleus accumbens, and this correlated with reduced H3K9me2 (Maze et al., 2010; Feng et al., 2014) . Conversely, they also showed that increasing EHMT1 and EHMT2 expression by pharmacologically inhibiting HDAC1/2 with MS-275 in combination with cocaine treatment or by sitedirected targeting of zinc-finger proteins fused with EHMT2 at the DfosB promoter caused an increase in global and site-specific H3K9me2 levels, respectively (Kennedy et al., 2013; Heller et al., 2014) . Unlike other repressive marks, H3K9me2 does not correlate with a terminally repressed state. Rather, it functions as a permissive tag to recruit a machinery that adds more stable repressive markers such as H3K9me3, H3K27me3, and DNA methylation through HP1 recruitment (Mozzetta et al., 2014; Rothbart and Strahl, 2014; Yearim et al., 2015) . Taken together, a picture is emerging in which H3K9me2 could act as an epigenetic mark SEM; bottom and top-most ***p < 0.001; n.s., non-significant; two-way ANOVA.
(E) mRNA expression analysis in the primary visual cortex from dark-reared (DR) and normal-reared (NR) WT and Ehmt1 +/À mice (n = 6-6) of Ehmt1, Ehmt2, and Bdnf IX. Data are presented as mean ± SEM; bottom and top-most *p < 0.05, **p < 0.01, ***p < 0.001; n.s., non-significant; n = 6-6; two-way ANOVA.
(F) Chromatin immunoprecipitation with H3K9me2 and qPCR analysis of the specified Bdnf promoter IV from WT and Ehmt1 +/À mice, dark-reared (DR) and normal-reared (NR), expressed as H3K9me2% input recovery. Data are presented as mean ± SEM (n = 6-6); bottom and top-most *p < 0.05; ***p < 0.001; n.s., non-significant; two-way ANOVA. See also Figure S6 .
that represents the activity state of a neuronal network and could serve as a general mechanism for poising a state in the genome in a ''ready to repress'' mode. H3K9me2 can thus be viewed as a dynamic regulatory histone mark as opposed to only a mark for heterochromatin.
EHMT1 Contributes to a Genomic Repressive Program Required for Scaling Up Synapses
Consistent with previous studies, we found that 48 hr of activity suppression mainly resulted in gene repression (Bateup et al., 2013b) . Interestingly, in EHMT1-deficient neurons, the set of genes implicated in synaptic scaling, showed aberrantly high basal expression and misregulated expression after TTX treatment. Essentially, there were fewer repressed genes compared to control neurons. GO analysis showed that the misregulated genes clustered in functional groups related to ion channel activity, potassium channel activity, synaptic vesicles, and calcium ion binding, suggesting that EHMT1 regulates these synapticscaling-related pathways. BDNF is a central mediator of homeostatic excitatory synaptic plasticity in vitro and in vivo : Desai et al., 1999 . Although Bdnf repression has been linked to synaptic scaling up, its transcriptional and epigenetic regulation has not been resolved Yu et al., 2015) . We show that EHMT1 and EHMT2 are both required to repress Bdnf expression during synaptic scaling up. Furthermore, we show that both are recruited specifically to Bdnf promoter IV after TTX treatment, leading to increased H3K9me2 at this promoter region, in vitro and in vivo. EHMT1 and EHMT2 are recruited to chromatin via their ankyrin repeats and anchor to histone H3 N terminals containing H3K9me1-2 (Collins et al., 2008) . Interestingly, EHMT1 has a higher affinity for H3K9me1 compared to EHMT2. Since we found that only EHMT2 and not EHMT1 protein levels increased after TTX, we propose a model in which EHMT1 serves as a scaffold, and during chronic network inactivity, EHMT1 may increase its association with EHMT2. Using co-immunoprecipitation experiments, we found that EHMT1 interacts significantly more with EHMT2 after TTX, supporting the above scenario. However, we cannot exclude that other mechanisms, including post-translational modifications, contribute to enhanced EHMT1/2 activity. An interesting finding from our studies is that scavenging BDNF excess in conditions of network deprivation restored the ability to scale up synapses in EHMT1-lacking cortical neurons. However, in contrast to controls, we could not increase mEPSC amplitudes by scavenging BDNF from untreated Ehmt1 knockdown neurons. This may be caused by disengagement of parallel signaling pathways normally recruited in conditions of lowered intracellular calcium concentration, therefore leading to a failure in synaptic scaling up in the Ehmt1 knockdown neurons. In addition, Bdnf levels are likely affected by other epigenetic mechanisms, such as DNA methylation and the activity of DNA methylation binding proteins, both of which rely on histone modifications (Yu et al., 2015) . This might explain why Bdnf upregulation was less pronounced in normally reared Ehmt1 +/À mice compared to neurons in vitro and might function as a compensatory mechanism to keep Bdnf expression within a normal range during development.
Another intriguing possibility is that EHMT1/2 cooperates with the Rett-syndrome-related protein MECP2 to repress gene transcription (Noh et al., 2012; Subbanna et al., 2014) . MECP2 is also required for synaptic scaling (Blackman et al., 2012; Chao et al., 2007; Qiu et al., 2012) . A recent study suggests that MeCP2 is involved in the repression of long genes (>100 kb). Interestingly, the same authors showed an overlap in the long genes that were misregulated in DNMT3A and MeCP2 knockdown mice (Gabel et al., 2015; Guo et al., 2014) . Elucidation of a this parallel action would be interesting to trace a potential cooperation between EHMT1/2 and MeCP2 in the repression of genes required for synaptic scaling up based on their gene body length.
Other genes that deserve attention are Arc and Rab3b. Both genes were repressed during synaptic scaling up, but not in EHMT1-lacking conditions. Although Arc mRNA levels failed to be repressed in EHMT1-deficient neurons, our experiments did not show any regulation of H3K9me2 levels at the promoter region of Arc. This suggests that Arc is only indirectly regulated by EHMT1, potentially via BDNF (Bateup et al., 2013b; Ji et al., 2010; Shepherd et al., 2006) . On the contrary, and similar to Bdnf, the changes in H3K9me2 at the Rab3b promoter were in line with a direct regulation of Rab3b by EHMT1 during synaptic scaling. Interestingly, at the Drosophila neuromuscular junction (NMJ), Rab3b has been suggested to facilitate homeostatic upregulation of presynaptic strength at a late stage of synaptic vesicle exocytosis by relieving an inhibitory control over homeostatic changes (Mü ller et al., 2011) . In mammals, Rab3b is enriched presynaptically at inhibitory synapses, where it is required for long-term depression (LTD) of hippocampal inhibitory synapses (Tsetsenis et al., 2011) and thus could potentially be involved in scaling of GABAergic synapses during homeostatic plasticity.
Further studies should be addressed to characterize the full complement of epigenetic events that characterize synaptic scaling. In this regard, sequencing for multiple histone modifications by analyzing in parallel different histone markers at different gene regulatory elements could provide further information of how the genome rearranges gene transcription in conditions of chronic deprivation in order to scale up synapses (Sun et al., 2012; Feng et al., 2014) .
Role of EHMT1 in Kleefstra Syndrome
Although loss of function of EHMT1 has directly been associated to Kleefstra syndrome, the nature of the synaptic deficits underlying the neurological symptoms has remained unclear. Previously, we found that LTP was unaffected in Ehmt1 +/À mice. We showed that pyramidal CA1 hippocampal neurons of Ehmt1 +/À mice had significant reductions in spine density, number of mature spines, and dendritic arborization, indicating a postsynaptic deficit (Balemans et al., 2013) . Decreased mEPSC frequency and increased paired-pulse facilitation indicated a presynaptic locus of action for EHMT1. In our current study, we found normal basal synaptic transmission in primary cortical neurons after EHMT1 knockdown and in layer II/III neurons from acute slices of Ehmt1 +/À mouse primary visual cortex. The discrepancies may derive from altered homeostatic regulation during development and/or could be attributable to brain region differences (Gupta-Agarwal et al., 2012 .
Unlike Hebbian plasticity, homeostatic plasticity has not been shown to directly influence learning and memory. However, the inability of a neuronal network to adapt to long-lasting changes in activity might lead to imbalances during development. In this way, loss of EHMT1/2 function could dynamically alter the responsiveness of a neuronal network to certain stimuli (Kennedy et al., 2013; Maze et al., 2010) and affect a wide range of cognitive functions.
EXPERIMENTAL PROCEDURES Electrophysiology
Whole-cell voltage clamp recordings were performed as previously described (Nadif Kasri et al., 2011) . In brief, for acute slices, mice (p23, Ehmt1 +/+ , and Ehmt1 +/À ) of both genotypes were anesthetized with isoflurane prior decapitation. 350-mm-thick coronal slices were cut using a microtome (HM650V, Thermo Scientific) in ice-cold artificial cerebrospinal fluid (ACSF) containing 87 mM NaCl, 11 mM glucose, 75 mM sucrose, 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 0.5 mM CaCl 2 , 7 mM MgCl 2 , and 26 mM NaHCO 3 continuously oxygenated with 95% O 2 /5% CO 2 and incubated for 1 hr at 32 C, after which they were allowed to cool down to room temperature. For recordings, acute slices or primary cortical neurons attached to glass coverslips were transferred to the recording setup and incubated in recording (ACSF) containing 124 mM NaCl, 1.25 mM NaH 2 PO 4 , 3 mM KCl, 26 mM NaHCO 3 , 10 mM glucose, 2 mM CaCl 2 , and 1 mM MgCl 2 continuously oxygenated with 95% O 2 /5% CO 2 at 30 C. Cells were visualized with an upright microscope (Olympus). Patch pipettes (5-7 MU) were made from borosilicate glass capillaries and filled with intracellular solution containing 115 mM CsMeSO 3 , 20 mM CsCl, 10 mM HEPES, 2.5 mM MgCl 2 , 4 mM Na 2 ATP, 0.4 mM NaGTP, 10 mM Naphosphocreatine, and 0.6 mM EGTA (pH 7.2-7.3, 285-295 mOsm). All experiments on animals were carried out in accordance with the approved animal care and use guidelines of the Animal Care Committee, Radboud University Nijmegen Medical Centre (RU-DEC-2011-021, protocol number: 77073).
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper is NCBI GEO: GSE68960. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
